IRIS UniCatt

Pera, Maria Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.606
AS - Asia 4.167
EU - Europa 3.749
SA - Sud America 780
AF - Africa 114
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.428
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.419
SG - Singapore 1.981
CN - Cina 847
DE - Germania 821
IT - Italia 810
BR - Brasile 637
SE - Svezia 443
NL - Olanda 409
VN - Vietnam 368
FR - Francia 340
IE - Irlanda 222
GB - Regno Unito 173
IN - India 153
JP - Giappone 147
ID - Indonesia 110
BD - Bangladesh 105
HK - Hong Kong 98
RU - Federazione Russa 92
FI - Finlandia 91
CA - Canada 87
KR - Corea 67
TR - Turchia 58
MX - Messico 56
PL - Polonia 56
AR - Argentina 55
ES - Italia 50
IQ - Iraq 49
UA - Ucraina 34
ZA - Sudafrica 30
AT - Austria 25
CZ - Repubblica Ceca 25
BE - Belgio 24
IL - Israele 24
PK - Pakistan 22
CH - Svizzera 20
CO - Colombia 19
VE - Venezuela 18
EC - Ecuador 17
IR - Iran 17
PA - Panama 17
RO - Romania 16
LT - Lituania 15
SA - Arabia Saudita 15
MA - Marocco 14
EG - Egitto 13
MK - Macedonia 13
PT - Portogallo 13
JO - Giordania 12
PH - Filippine 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 11
CI - Costa d'Avorio 11
RS - Serbia 11
UZ - Uzbekistan 11
KE - Kenya 9
PY - Paraguay 8
UY - Uruguay 8
NP - Nepal 7
OM - Oman 7
PE - Perù 7
AL - Albania 6
BG - Bulgaria 6
KZ - Kazakistan 6
MY - Malesia 6
AU - Australia 5
CL - Cile 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
HR - Croazia 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
AZ - Azerbaigian 4
BO - Bolivia 4
GR - Grecia 4
KG - Kirghizistan 4
LU - Lussemburgo 4
NZ - Nuova Zelanda 4
TH - Thailandia 4
BH - Bahrain 3
CR - Costa Rica 3
DZ - Algeria 3
HN - Honduras 3
LK - Sri Lanka 3
LY - Libia 3
NG - Nigeria 3
NI - Nicaragua 3
BT - Bhutan 2
BY - Bielorussia 2
DM - Dominica 2
EE - Estonia 2
GE - Georgia 2
HU - Ungheria 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
ME - Montenegro 2
PR - Porto Rico 2
SI - Slovenia 2
SV - El Salvador 2
TW - Taiwan 2
Totale 13.400
Salva come PNG Salva come JPEG
Città #
Singapore 1.172
Ashburn 618
San Jose 522
Chandler 460
Amsterdam 367
Frankfurt am Main 277
New York 222
Rome 211
Dublin 203
Hefei 184
Los Angeles 163
Tukwila 151
Beijing 144
Tokyo 139
Milan 122
Ho Chi Minh City 120
Jakarta 102
Lauterbourg 100
Hanoi 93
Hong Kong 87
Chicago 73
São Paulo 68
Seoul 66
Boston 65
Munich 64
Dallas 61
Kent 53
Helsinki 51
The Dalles 48
Marseille 47
Buffalo 46
Moscow 43
Santa Clara 43
Pune 38
San Mateo 38
Orem 37
Warsaw 37
Princeton 36
Boardman 35
London 34
Council Bluffs 33
Nuremberg 33
Paris 33
Atlanta 32
Denver 32
Montreal 31
Houston 28
Toronto 25
Chennai 24
Brooklyn 23
Poplar 23
Rio de Janeiro 23
Stockholm 22
Ann Arbor 21
Baghdad 21
Johannesburg 21
Mexico City 21
Palermo 21
Shanghai 21
Dearborn 20
Wilmington 20
Brussels 19
Da Nang 18
Düsseldorf 18
Nanjing 18
Belo Horizonte 17
Bremen 17
San Francisco 17
Seattle 17
Ankara 16
Brno 16
Haiphong 16
Turku 16
Hyderabad 15
Lappeenranta 15
Falkenstein 14
Jacksonville 14
Turin 14
Brasília 13
Columbus 13
Phoenix 13
Amman 12
Augusta 12
Bexley 12
Portsmouth 12
Vienna 12
Abidjan 11
Biên Hòa 11
Cattolica 11
Charlotte 11
Redwood City 11
St Louis 11
Andover 10
Bari 10
Bologna 10
City of London 10
Curitiba 10
Dhaka 10
Edinburgh 10
Florence 10
Totale 7.490
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 960
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 272
Assessing floppy infants: a new module 212
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 202
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 191
Developmental milestones in type I spinal muscular atrophy 190
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 186
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 181
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 179
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 165
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 165
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 165
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 165
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 161
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 160
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 157
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 156
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 154
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 151
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 149
Predominant distal muscle involvement in spinal muscular atrophy 148
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 147
Revised upper limb module for spinal muscular atrophy: Development of a new module 146
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 143
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 142
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 139
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 137
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 136
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 135
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 135
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 135
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 134
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 134
Early treatment of type II SMA slows rate of progression of scoliosis 133
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 133
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 133
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 131
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 129
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 127
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 127
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 126
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 124
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 123
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 123
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 122
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 121
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 118
Sleep disorders in spinal muscular atrophy 117
New therapies for spinal muscular atrophy: where we stand and what is next 117
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 117
Developmental milestones in type I spinal muscular atrophy 117
Revised upper limb module for spinal muscular atrophy: Development of a new module 114
Clinical Variability in Spinal Muscular Atrophy Type III. 114
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 114
An observational study of functional abilities in infants, children, and adults with type 1 SMA 112
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 112
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 111
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 108
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 106
Development of an academic disease registry for spinal muscular atrophy 106
Risdiplam in Type 1 Spinal Muscular Atrophy 105
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 105
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 103
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 99
Longitudinal natural history of type I spinal muscular atrophy: A critical review 98
An observational study of functional abilities in infants, children, and adults with type 1 SMA 97
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 97
Gain and loss of abilities in type II SMA: A 12-month natural history study 97
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 94
Long term follow-up of scoliosis progression in type II SMA patients 93
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 93
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 91
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 90
Old measures and new scores in spinal muscular atrophy patients 90
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 89
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 88
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 88
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data 88
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 87
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 87
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage 86
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 86
Pregnancy in the Era of Disease-Modifying Therapies for Spinal Muscular Atrophy: Considerations From a Case Report 84
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 84
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 83
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 83
null 81
Spinal muscular atrophy — insights and challenges in the treatment era 81
Neonatal hypotonia and neuromuscular conditions 80
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 80
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 79
Risdiplam in Type 1 Spinal Muscular Atrophy 78
Revised upper limb module for spinal muscular atrophy: 12 month changes 77
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 76
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 74
Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update 74
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 73
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 71
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 71
Early neurodevelopmental assessment in Duchenne muscular dystrophy 70
Totale 12.817
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.210
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.210
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/2022449 30 6 5 63 34 13 9 63 33 27 70 96
2022/20231.646 108 175 109 222 109 201 104 169 253 42 90 64
2023/20241.332 44 268 51 136 51 243 142 59 18 68 110 142
2024/20252.411 49 43 158 115 194 125 102 96 338 203 540 448
2025/20267.438 806 209 429 885 1.210 1.220 1.061 290 364 410 381 173
Totale 13.589